Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
advocate, aforementioned, AgreementSM, AgreementSMwith, attrition, baby, bona, bore, Brazil, burn, CCPA, cerebrospinal, Citigroup, clause, Colorado, combat, counterfeit, CPRA, cyber, cyberattack, deployment, depressing, destruction, downgrade, dry, electroencephalogram, email, espionage, excessive, excise, eye, fatigue, fide, flexibility, float, fulfill, glioblastoma, GMP, gouging, headache, HIV, hostile, hyperbilirubinemia, hypesthesia, hypoesthesia, hypotension, ID, Indian, instated, landlord, lift, lifted, lifting, ligament, mailing, malware, marker, Mike, MoCA, Moma, Montreal, moratorium, multi, multidose, multiforme, myalgia, NaN, Needham, orthostatic, pain, paused, payoff, penny, pharmacovigilance, PHI, phone, qEEG, rarity, reconsider, remedy, resumption, roster, RSA, seventeen, slightly, stolen, Subtenant, supervisory, surrender, synaptic, TCA, threat, timetable, tracing, transitory, transmit, twenty, unfit, Unified, unsolicited, vaccination, Virginia, visibility, winding, wire, withdrew, workforce, worsening, worth, Wyzga
Removed:
accomplish, aim, appeal, assay, attracting, beneficial, beneficiary, biologic, clinic, Columbia, conceal, concurrent, correspondingly, database, derive, display, efficiently, eventually, Genentech, inexpensive, lawful, lowering, medicine, partnering, precedent, prefer, proof, proposal, qui, rationale, reimbursable, reward, safeguarding, scaling, simple, soliciting, tam, thereto, translate, translational, Treaty, turnover, whistleblower
Filing tables
Filing exhibits
Related press release
KANT similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-261489 and 333-252695) and Form S-8 (Nos. 333- 256853, 333-252692, 333-252691, 333-237181, 333-230155, 333-223664, 333-218544 and 333-210521) of Yumanity Therapeutics, Inc. of our report dated March 24, 2022 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 24, 2022